In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.63 below Quoin Pharmaceuticals Ltd average.

Within Major Pharmaceutical Preparations industry 314 other companies have achieved higher Quick Ratio than Quoin Pharmaceuticals Ltd in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 465 to 1423.

Explain Quick Ratio?
How much Cash & cash equivalents QNRX�s has?
What are QNRX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

QNRX Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	52.46 %	10.1 %	32.67 %	65.95 %	9.74 %
Y / Y Cash & cash equivalent Change	39.02 %	21.88 %	33.35 %	-47.36 %	-38.08 %
Quick Ratio MRQ	1.63	2.63	3.38	0.94	1.79
QNRX's Total Ranking	# 1423	# 465	# 808	# 2369	# 2067
Seq. Current Liabilities Change	23.7 %	-3.62 %	-3.78 %	32.9 %	-10.67 %
Seq. Cash & cash equivalent Change	-23.09 %	-25.08 %	245.16 %	-30.09 %	-32.58 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 315
Healthcare Sector	# 550
Overall Market	# 1423

Quick Ratio Statistics
High	Average	Low
8.19	3.66	0.94
(Sep 30 2022)		(Sep 30 2025)

Financial Statements
Quoin Pharmaceuticals Ltd 's Current Liabilities	$ 7 Millions	Visit QNRX's Balance sheet
Quoin Pharmaceuticals Ltd 's Cash & cash equivalent	$ 11 Millions	Visit QNRX's Balance sheet
Source of QNRX's Sales		Visit QNRX's Sales by Geography

Cumulative Quoin Pharmaceuticals Ltd 's Quick Ratio

QNRX's Quick Ratio for the trailling 12 Months

QNRX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	38.12 %	27.53 %	29.52 %	25.65 %	3.12 %
Y / Y Cash & cash equivalent TTM Growth	12.26 %	-5.06 %	-15.85 %	-19.71 %	-15.94 %
Quick Ratio TTM	2.11	2.19	2.12	2.03	2.59
Total Ranking TTM	# 3873	# 1787	# 3035	# 3035	# 2861
Seq. Current Liabilities TTM Growth	10.84 %	2.39 %	7.14 %	13.6 %	2.34 %
Seq. Cash & cash equivalent TTM Growth	6.59 %	5.8 %	12.09 %	-11.19 %	-9.86 %

Quick ratio ranking by company, industry and sector >> Back to QNRX Financial Strength Comparisons >> Go to Compare QNRX Quick Ratio to its Competitors

News about Quoin Pharmaceuticals Ltd Quick Ratio

Quoin Pharmaceuticals Pioneering New Frontiers in Rare Disease Therapeutics

Breaking New Ground in Pediatric Netherton Syndrome Quoin Pharmaceuticals Ltd., a prominent player in the niche domain of rare and orphan diseases, is making significant strides in advancing clinical research and therapeutic avenues. Recently, the company announced a critical development in its pediatric Netherton Syndrome (NS) study. The ongoing investigator-led study that is charting new territories has successfully enrolled three additional patients, broadening the scope and robustness of the research. This expansion comes on the heels of an impressive 9-month data update from the very first pediatric participant, showcasing promising outcomes that signal a potential breakthrough in the treatment of NS. Promising Advances in Peeling Skin Syndrome In tandem with its efforts in Netherton Syndrome, Quoin Pharmaceuticals is also garnering attention for its pioneering work in Pediatric Peeling Skin Syndrome. Earlier this year, Quoin unveiled initial positive clinical data from this ongoing study, reinforcing its commitment to tackling rare dermatological conditions. The encouraging findings amplify the potential of Quoin’s therapeutic interventions, offering hope to patients grappling with these debilitating skin conditions.

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $6.61 millions, cumulative Quick Ratio decreased to 2.11 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Quoin Pharmaceuticals Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 1787 to 3873.

Explain Quick Ratio?
How much Cash & cash equivalents QNRX�s has?
What are QNRX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 433
Healthcare Sector	# 886
Within the Market	# 3873

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.75	3.43	2.03
(Dec 31 2020)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Quantum Cyber N v	4.46	$ 13.415 Millions	$ 3.005 Millions
Maia Biotechnology Inc	4.41	$ 27.596 Millions	$ 6.258 Millions
Azitra Inc	4.40	$ 6.728 Millions	$ 1.531 Millions
Cypherpunk Technologies Inc	4.39	$ 7.624 Millions	$ 1.737 Millions
Rigel Pharmaceuticals Inc	4.35	$ 225.347 Millions	$ 51.858 Millions
Biohaven Ltd	4.28	$ 267.866 Millions	$ 62.658 Millions
Incannex Healthcare Inc	4.25	$ 67.711 Millions	$ 15.940 Millions
Longeveron Inc	4.20	$ 18.104 Millions	$ 4.307 Millions
Vistagen Therapeutics Inc	4.15	$ 46.439 Millions	$ 11.192 Millions
Gyre Therapeutics Inc	4.12	$ 86.289 Millions	$ 20.957 Millions
Seaport Therapeutics Inc	4.11	$ 64.423 Millions	$ 15.674 Millions
Prelude Therapeutics Inc	3.99	$ 151.757 Millions	$ 38.042 Millions
Alx Oncology Holdings Inc	3.97	$ 22.753 Millions	$ 5.731 Millions
Actinium Pharmaceuticals Inc	3.94	$ 36.473 Millions	$ 9.260 Millions
Veru Inc	3.88	$ 23.880 Millions	$ 6.156 Millions
Gain Therapeutics inc	3.81	$ 13.084 Millions	$ 3.434 Millions
Bolt Biotherapeutics Inc	3.79	$ 29.823 Millions	$ 7.867 Millions
Acurx Pharmaceuticals inc	3.72	$ 10.656 Millions	$ 2.865 Millions
Maplight Therapeutics Inc	3.71	$ 71.633 Millions	$ 19.294 Millions
Aptevo Therapeutics Inc	3.47	$ 17.997 Millions	$ 5.188 Millions
Ataibeckley Inc	3.43	$ 168.807 Millions	$ 49.221 Millions
Dogwood Therapeutics inc	3.40	$ 9.628 Millions	$ 2.831 Millions
Tvardi Therapeutics Inc	3.39	$ 30.865 Millions	$ 9.113 Millions
Biomea Fusion Inc	3.32	$ 34.824 Millions	$ 10.483 Millions
Abeona Therapeutics Inc	3.32	$ 146.826 Millions	$ 44.233 Millions
Foghorn Therapeutics Inc	3.31	$ 167.582 Millions	$ 50.579 Millions
Cingulate Inc	3.29	$ 28.403 Millions	$ 8.631 Millions
Unicycive Therapeutics Inc	3.28	$ 61.425 Millions	$ 18.704 Millions
Harmony Biosciences Holdings inc	3.17	$ 667.791 Millions	$ 210.812 Millions
Pulmatrix Inc	3.15	$ 2.168 Millions	$ 0.689 Millions

Date modified: 2026-08-16T08:52:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.